

Committed to clinical outcomes that meet your demands.



Pre-Post EVAR Case Example



AFX[®]2
Endovascular AAA System

Before



After



The AFX[®]2 System and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to **Instructions for Use** for more information concerning Indications, Contraindications, Warnings, Precautions, and Adverse Events. Rx only.

Endologix is a registered trademark of Endologix LLC in the United States, Europe and Japan and AFX2 is a registered trademark of Endologix LLC and its subsidiaries. All other trademarks are the property of their respective owners. ©2023 Endologix LLC. All rights reserved. MM2687-ALL Rev 01



Committed to clinical outcomes that meet your demands.

INDICATIONS FOR USE- US:

The Endologix® AFX®2 Endovascular AAA Systems are indicated for treatment of patients with abdominal aortic aneurysms having the vascular morphology suitable for endovascular repair using a surgical vascular access technique or a bilateral percutaneous technique; a non-aneurysmal aortic neck between the renal arteries and the aneurysm: with length of $\geq 15\text{mm}$, diameter ≥ 18 to $\leq 32\text{mm}$ and neck angle of $\leq 60^\circ$ to the body of the aneurysm; aortic length $\geq 1.0\text{cm}$ longer than the body portion of the chosen bifurcated model; common iliac artery distal fixation site with length $\geq 15\text{mm}$, diameter of ≥ 10 to $\leq 23\text{mm}$, and with ability to preserve at least one hypogastric artery; and with an iliac angle of $\leq 90^\circ$ to the aortic bifurcation. Extension stent grafts must have the ability to overlap the bifurcated stent graft by at least 30 to 40mm proximally and at least 15 to 20mm distally.

CONTRAINDICATIONS- US:

The Endologix® AFX®2 Endovascular AAA Systems are contraindicated for use in patients who have a condition that threatens to infect the graft and in patients with sensitivities or allergies to the device materials. Refer to the Instructions for Use for more information concerning Indications, Contraindications, Warnings and Precautions, and Adverse Events.

INDICATIONS FOR USE- EU:

The Endologix® AFX®2 Endovascular AAA Systems are indicated for treatment of patients with abdominal aortic aneurysms having the vascular morphology suitable for endovascular repair using a surgical vascular access technique; a non-aneurysmal aortic neck between the renal arteries and the aneurysm: with length of $\geq 15\text{mm}$, diameter ≥ 18 to $\leq 32\text{mm}$ and neck angle of $\leq 60^\circ$ to the body of the aneurysm; aortic length $\geq 1.0\text{cm}$ longer than the body portion of the chosen bifurcated model; common iliac artery distal fixation site with length $\geq 15\text{mm}$, diameter of ≥ 10 to $\leq 23\text{mm}$, and with ability to preserve at least one hypogastric artery; and with an iliac angle of $\leq 90^\circ$ to the aortic bifurcation. Extension stent grafts must have the ability to overlap the bifurcated stent graft by at least 30 to 40mm proximally and at least 15 to 20mm distally.

CONTRAINDICATIONS- EU:

The Endologix® AFX®2 Endovascular AAA Systems are contraindicated for use in patients who have a condition that threatens to infect the graft and in patients with known sensitivities or allergies to the device materials. Refer to the Instructions for Use for more information concerning Indications, Contraindications, Warnings and Precautions, and Adverse Events.

CAUTION:

Federal (USA) law restricts this device to sale by or on the order of a physician. Rx only.

NOTE:

Endologix products and associated components are not available in all countries or regions. Please consult with your Endologix representative for details regarding product availability. CE marked. Please refer to current product instructions for use. Endologix®, AFX®2, DuraPly®, VELA®, and ActiveSeal® are registered trademarks of Endologix LLC in the United States and certain foreign countries. All other trademarks are the property of their respective owners. ©2023 Endologix LLC. All rights reserved. MM2687-US Rev 01